Contact

E-mail:yunlongcao@pku.edu.cn
Add:Rm. 102, Biomedical Pioneering Innovation Center, Integrated Science Research Center No.2,Peking University

Lab Web:http://yunlongcaolab.com/

Yunlong Cao
PI
Resume

2024-Present Peking-Tsinghua Center for Life Sciences, Principal Investigator
2023-Present Peking University, Assistant Professor/Principal Investigator 
2019-2023 Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Research Associate
2014-2019 Department of Chemistry and Chemical Biology, Harvard University, Ph.D. in Chemistry (Advisor: Xiaoliang Sunney Xie)
2010-2014 Chu Kochen Honors College, Zhejiang University, B.S. in Physics

 
Research Interests
Cao Lab investigates humoral immunity and antibodies at single-cell and molecular level. Our research interests include the following aspects:
  • Antibody response, immune escape and immune imprinting in infectious diseases;
  • Development of broad-spectrum antibody therapeutics and vaccines;
  • Deciphering the relationship between targeting epitopes and functions of antibodies for various antigens;
  • Computational and machine learning methods for modeling antibody-antigen interaction.

 

Awards and Honors
2023 Beijing Outstanding Yound Talent Award (ZhongGuanCun Award)
2023 WHO Technical Advisory Group on COVID-19 Vaccine Composition (TAG-CO-VAC 2023)
2023 The Coalition for Epidemic Preparedness Innovations (CEPI) Scientific Advisory Committee
2023 China's top 10 scientific advances in 2022
2023 China's top 10 advances in life sciences in 2022
2022 Nature’s “Ten people who helped shape science in 2022” (Nature’s 10) 
2022 MIT Technology Review Innovators Under 35 China (TR35 China)
 
Selected Publication​​
  1. A. Yisimayi#, W. Song#, J. Wang#, F. Jian#, Y. Yu#, X. Chen#, Y. Xu#, S. Yang, X. Niu, T. Xiao, J. Wang, L. Zhao, H. Sun, R. An, N. Zhang, Y. Wang, P. Wang, L. Yu, Z. Lv, Q. Gu, F. Shao, R. Jin, Z. Shen, X. S. Xie, Y. Wang & Y. Cao*, Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Nature. 625: 148-156. (2024).

  2. Y. Cao*#, F. Jian#, J. Wang#, Y. Yu#, W. Song#, A. Yisimayi, J. Wang, R. An, X.Chen, N. Zhang, Y. Wang, P. Wang,L. Zhao, H. Sun, L. Yu, S. Yang, X. Niu, T. Xiao, Q. Gu, F. Shao, X. Xiao, Y. Xu, R. Jin, Z. Shen, Y. Wang* & X.S. Xie*, Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 614: 21-529. (2023).

  3. Y. Cao*#, A. Yisimayi#, F. Jian#, W. Song#, T. Xiao#, L. Wang#, S. Du#, J. Wang#, Q. Li#, X. Chen#, Y. Yu#, P. Wang,Z. Zhang, P. Liu, R. An, X. Hao, Y. Wang, J. Wang, R. Feng, H. Sun, L. Zhao, W. Zhang, D. Zhao, J. Zheng, L. Y,C. Li, N. Zhang, R. Wang, X. Niu, S. Yang, X. Song, Y. Chai, Y. Hu, Y. Shi, L. Zheng, Z. Li, Q. Gu, F. Shao, W.Huang, R. Jin, Z. Shen*, Y. Wang*, X. Wang*, J. Xiao* & X. S. Xie*, BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 608: 593-602. (2022).

  4. Y. Cao*#, J. Wang#, F. Jian#, T. Xiao#, W. Song#, A. Yisimayi#, W. Huang#, Q. Li, P. Wang, R. An, J. Wang, Y. Wang, X. Niu, S. Yang, H. Liang, H. Sun, T. Li, Y. Yu, Q. Cui, S. Liu, X. Yang, S. Du, Z. Zhang, X. Hao, F. Shao,R. Jin, X. Wang*, J. Xiao*, Y. Wang* & X. S. Xie*, Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 602: 657-663. (2022).

  5. Y. Cao#, B. Su#, X. Guo#, W. Sun#, Y. Deng#, L. Bao#, Q. Zhu, X. Zhang, Y. Zheng, C. Geng, X. Chai, R. He, X. Li,Q. Lv, H. Zhu, W. Deng, Y. Xu, Y. Wang, L. Qiao, Y. Tan, L. Song, G. Wang, X. Du, N. Gao, J. Liu, J. Xiao, X. Su,Z. Du, Y. Feng, C. Qin*, C. Qin*, R. Jin*, X. S. Xie*, Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells. Cell. 182: 73-84.e16 (2020).

  6. S. Yang#, Y. Yu#, Y. Xu, F. Jian, W. Song, A. Yisimayi, P. Wang, J. Wang, J. Liu, L. Yu, X. Niu, J. Wang, Y. Wang, F. Shao, R. Jin, Y. Wang, Y. Cao*, Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. The Lancet Infectious Diseases. 24(2): e70-e72 (2024).

  7. S. Yang#, Y. Yu#, F. Jian, W. Song, A. Yisimayi, X. Chen, Y. Xu, P. Wang, J. Wang, L. Yu, X. Niu, J. Wang, T. Xiao, R. An, Y. Wang, Q. Gu, F. Shao, R. Jin, Z. Shen, Y. Wang, Y. Cao*, Antigenicity and infectivity characterization of SARS-CoV-2 BA.2.86. The Lancet Infectious Diseases. 23(11): e457-e459 (2023).

  8. C. Yue, W. Song, L. Wang, F. Jian, X. Chen, F. Gao, Z. Shen, Y. Wang, X. Wang*, Y. Cao*, ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. The Lancet Infectious Diseases. 23(3):278-280 (2023).

  9. Z. Cui#, P. Liu#, N. Wang#, L. Wang#, K. Fan#, Q. Zhu#, K. Wang#, R. Chen, R. Feng, Z. Jia, M. Yang, G. Xu, B. Zhu, W. Fu, T. Chu, L. Feng, Y. Wang, X. Pei, P. Yang, X. S. Xie, L. Cao*, Y. Cao*, X. Wang*, Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell. 185(5): 860-871. (2022).

  10. S. Du#, Y. Cao#, Q. Zhu#, P. Yu#, F. Qi#, G. Wang, ...A. Yisimayi, Q. Lv, B. Wang, R. He, Y. Han, W. Zhao, Y. Bai, Y. Qu, X. Gao, C. Ji,Q. Wang, N. Gao, W. Huang, Y. Wang, X. S. Xie*, X. Su*, J. Xiao*, C. Qin*, Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. Cell. 183: 1013-1023.e13 (2020).